According to Tudor Pickering, the prior rating for Range Resources Corp (NYSE:RRC) was changed from Hold to Buy. For the fourth quarter, Range Resources had an EPS of $1.30, compared to year-ago quarter EPS of $0.96. At the moment, the stock has a 52-week-high of $37.39 and a 52-week-low of $22.61. Range Resources closed at $23.33 at the end of the last trading period.

According to Morgan Stanley, the prior rating for Harley-Davidson Inc (NYSE:HOG) was changed from Equal-Weight to Overweight. Harley-Davidson earned $0.28 in the fourth quarter, compared to $0.15 in the year-ago quarter. The current stock performance of Harley-Davidson shows a 52-week-high of $51.77 and a 52-week-low of $29.82. Moreover, at the end of the last trading period, the closing price was at $37.55.

Piper Sandler upgraded the previous rating for Wix.com Ltd (NASDAQ:WIX) from Neutral to Overweight. For the fourth quarter, Wix.com had an EPS of $0.61, compared to year-ago quarter EPS of $0.37. The current stock performance of Wix.com shows a 52-week-high of $111.33 and a 52-week-low of $53.12. Moreover, at the end of the last trading period, the closing price was at $88.38.

Piper Sandler upgraded the previous rating for Vornado Realty Trust (NYSE:VNO) from Underweight to Neutral. Vornado Realty earned $0.72 in the fourth quarter, compared to $0.81 in the year-ago quarter. The current stock performance of Vornado Realty shows a 52-week-high of $47.11 and a 52-week-low of $13.80. Moreover, at the end of the last trading period, the closing price was at $14.38.

Raymond James upgraded the previous rating for Fleetcor Technologies Inc (NYSE:FLT) from Market Perform to Outperform. Fleetcor Technologies earned $4.04 in the fourth quarter, compared to $3.72 in the year-ago quarter. The stock has a 52-week-high of $265.02 and a 52-week-low of $162.98. At the end of the last trading period, Fleetcor Technologies closed at $199.08.

According to Telsey Advisory Group, the prior rating for Foot Locker Inc (NYSE:FL) was changed from Market Perform to Outperform. In the fourth quarter, Foot Locker showed an EPS of $0.97, compared to $1.67 from the year-ago quarter. The current stock performance of Foot Locker shows a 52-week-high of $47.22 and a 52-week-low of $23.86. Moreover, at the end of the last trading period, the closing price was at $39.86.

According to Morgan Stanley, the prior rating for Meta Platforms Inc (NASDAQ:META) was changed from Equal-Weight to Overweight. Meta Platforms earned $1.76 in the fourth quarter, compared to $3.67 in the year-ago quarter. The current stock performance of Meta Platforms shows a 52-week-high of $205.76 and a 52-week-low of $88.10. Moreover, at the end of the last trading period, the closing price was at $197.81.

For Armstrong World Industries Inc (NYSE:AWI), Deutsche Bank downgraded the previous rating of Buy to Hold. For the fourth quarter, Armstrong World Indus had an EPS of $1.08, compared to year-ago quarter EPS of $1.09. The stock has a 52-week-high of $96.51 and a 52-week-low of $67.14. At the end of the last trading period, Armstrong World Indus closed at $69.45.

According to Maxim Group, the prior rating for Cyclo Therapeutics Inc (NASDAQ:CYTH) was changed from Buy to Hold. Cyclo Therapeutics earned $0.59 in the fourth quarter, compared to $0.34 in the year-ago quarter. The current stock performance of Cyclo Therapeutics shows a 52-week-high of $3.35 and a 52-week-low of $0.86. Moreover, at the end of the last trading period, the closing price was at $0.94.

Ladenburg Thalmann downgraded the previous rating for Athenex Inc (NASDAQ:ATNX) from Buy to Neutral. Athenex earned $4.28 in the fourth quarter, compared to $6.40 in the year-ago quarter. The current stock performance of Athenex shows a 52-week-high of $24.00 and a 52-week-low of $1.24. Moreover, at the end of the last trading period, the closing price was at $1.26.

Piper Sandler downgraded the previous rating for GoDaddy Inc (NYSE:GDDY) from Overweight to Neutral. In the fourth quarter, GoDaddy showed an EPS of $0.60, compared to $0.52 from the year-ago quarter. The current stock performance of GoDaddy shows a 52-week-high of $88.30 and a 52-week-low of $64.69. Moreover, at the end of the last trading period, the closing price was at $74.40.

Jefferies downgraded the previous rating for Profound Medical Corp (NASDAQ:PROF) from Buy to Equal-Weight. For the fourth quarter, Profound Medical had an EPS of $0.46, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $13.52 and a 52-week-low of $3.10. Profound Medical closed at $10.16 at the end of the last trading period.

For Agree Realty Corp (NYSE:ADC), JMP Securities downgraded the previous rating of Market Outperform to Market Perform. For the fourth quarter, Agree Realty had an EPS of $0.95, compared to year-ago quarter EPS of $0.91. The current stock performance of Agree Realty shows a 52-week-high of $80.41 and a 52-week-low of $63.34. Moreover, at the end of the last trading period, the closing price was at $68.84.

According to Wolfe Research, the prior rating for Oak Street Health Inc (NYSE:OSH) was changed from Outperform to Peer Perform. In the fourth quarter, Oak Street Health showed an EPS of $0.56, compared to $0.62 from the year-ago quarter. The stock has a 52-week-high of $35.84 and a 52-week-low of $13.35. At the end of the last trading period, Oak Street Health closed at $35.70.

Stifel downgraded the previous rating for Electrameccanica Vehicles Corp Ltd (NASDAQ:SOLO) from Buy to Hold. In the third quarter, Electrameccanica Vehicles showed an EPS of $0.18, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $2.44 and a 52-week-low of $0.57. At the end of the last trading period, Electrameccanica Vehicles closed at $0.58.

SVB Leerink initiated coverage on Rain Oncology Inc (NASDAQ:RAIN) with an Outperform rating. The price target for Rain Oncology is set to $11.00. For the fourth quarter, Rain Oncology had an EPS of $0.70, compared to year-ago quarter EPS of $0.68. The stock has a 52-week-high of $14.48 and a 52-week-low of $2.18. At the end of the last trading period, Rain Oncology closed at $7.77.

Bernstein initiated coverage on Vertex Pharmaceuticals Inc (NASDAQ:VRTX) with an Outperform rating. The price target for Vertex Pharmaceuticals is set to $344.00. Vertex Pharmaceuticals earned $3.76 in the fourth quarter, compared to $3.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $325.19 and a 52-week-low of $233.14. Vertex Pharmaceuticals closed at $298.95 at the end of the last trading period.

With an Underperform rating, Bernstein initiated coverage on Biomarin Pharmaceutical Inc (NASDAQ:BMRN). The price target seems to have been set at $81.00 for Biomarin Pharmaceutical. In the fourth quarter, Biomarin Pharmaceutical showed an EPS of $0.00, compared to $0.32 from the year-ago quarter. The current stock performance of Biomarin Pharmaceutical shows a 52-week-high of $117.77 and a 52-week-low of $70.76. Moreover, at the end of the last trading period, the closing price was at $92.34.

Bernstein initiated coverage on Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) with an Outperform rating. The price target for Alnylam Pharmaceuticals is set to $243.00. Alnylam Pharmaceuticals earned $1.39 in the fourth quarter, compared to $1.74 in the year-ago quarter. The stock has a 52-week-high of $242.74 and a 52-week-low of $117.62. At the end of the last trading period, Alnylam Pharmaceuticals closed at $187.52.

With an Outperform rating, Bernstein initiated coverage on Intellia Therapeutics Inc (NASDAQ:NTLA). The price target seems to have been set at $54.00 for Intellia Therapeutics. For the fourth quarter, Intellia Therapeutics had an EPS of $1.40, compared to year-ago quarter EPS of $1.09. At the moment, the stock has a 52-week-high of $78.58 and a 52-week-low of $32.44. Intellia Therapeutics closed at $38.27 at the end of the last trading period.

Bernstein initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating. The price target for Beam Therapeutics is set to $37.00. Beam Therapeutics earned $0.54 in the fourth quarter, compared to $0.95 in the year-ago quarter. The current stock performance of Beam Therapeutics shows a 52-week-high of $73.26 and a 52-week-low of $27.90. Moreover, at the end of the last trading period, the closing price was at $32.23.

With a Market Perform rating, Bernstein initiated coverage on Allogene Therapeutics Inc (NASDAQ:ALLO). The price target seems to have been set at $6.00 for Allogene Therapeutics. For the fourth quarter, Allogene Therapeutics had an EPS of $0.66, compared to year-ago quarter EPS of $0.54. At the moment, the stock has a 52-week-high of $17.48 and a 52-week-low of $5.27. Allogene Therapeutics closed at $5.37 at the end of the last trading period.

Bernstein initiated coverage on CRISPR Therapeutics AG (NASDAQ:CRSP) with a Market Perform rating. The price target for CRISPR Therapeutics is set to $44.00. CRISPR Therapeutics earned $1.41 in the fourth quarter, compared to $1.84 in the year-ago quarter. The stock has a 52-week-high of $86.79 and a 52-week-low of $38.94. At the end of the last trading period, CRISPR Therapeutics closed at $44.46.

Bernstein initiated coverage on Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) with a Market Perform rating. The price target for Arrowhead Pharma is set to $27.00. Arrowhead Pharma earned $0.39 in the first quarter, compared to $0.60 in the year-ago quarter. The stock has a 52-week-high of $51.01 and a 52-week-low of $23.09. At the end of the last trading period, Arrowhead Pharma closed at $25.06.

With an Underperform rating, Bernstein initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS). The price target seems to have been set at $31.00 for Ionis Pharmaceuticals. For the fourth quarter, Ionis Pharmaceuticals had an EPS of $1.18, compared to year-ago quarter EPS of $1.55. The stock has a 52-week-high of $48.82 and a 52-week-low of $31.46. At the end of the last trading period, Ionis Pharmaceuticals closed at $35.60.

Wells Fargo initiated coverage on Ventyx Biosciences Inc (NASDAQ:VTYX) with an Overweight rating. The price target for Ventyx Biosciences is set to $77.00. Ventyx Biosciences earned $0.59 in the third quarter, compared to $3.17 in the year-ago quarter. The current stock performance of Ventyx Biosciences shows a 52-week-high of $47.25 and a 52-week-low of $9.96. Moreover, at the end of the last trading period, the closing price was at $37.85.